MedTrace Logo

The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy.

NCT00405015 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2010-08-24

No results posted yet for this study

Summary

Cardiovascular disease is the leading cause of death in diabetic patients due to both a high event rate and a worse outcome. A pharmacological intervention that reduces ischemia-reperfusion-injury would improve the outcome of diabetic patients after a cardiovascular event. In the present study, we will use annexinA5 scintigraphy to address the following hypothesis:

Rosiglitazone reduces ischemia-reperfusion-injury in humans with insulin resistance.

Conditions

  • Ischemia-Reperfusion Injury
  • The Metabolic Syndrome

Interventions

DRUG

rosiglitazone

Rosiglitazone 4 mg bidaily for 8 weeks

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Gerard A Rongen, MD, PhD · Radboud University Nijmegen Medical Center, department pharmacology-Toxicology

  • Alexander JM Rennings, MD · Radboud University Nijmegen Medical Center, department of pharmacology-Toxicology

  • Paul Smits, MD, PhD · Radboud University Nijmegen Medical Center, head of department of Parmacology-Toxicology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2008-07-31
Completion
2008-10-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00405015 on ClinicalTrials.gov